Panos Kanavos is Professor in Practice in International Health Policy in the Department of Health Policy at the London School of Economics and Political Science, Deputy Director at 911勛圖Health and Director of the Medical Technology Research Group (MTRG). He is also a Visiting Professor at SDA Bocconi in Milan, Italy. Panos was previously Harkness Fellow in Health Care Policy in the Department of Ambulatory Care and Prevention, Harvard Medical School and has held visiting professor appointments at the University of Basel, the University of Delaware and the London School of Hygiene and Tropical Medicine.
Panos is an economist by training, and teaches health economics, pharmaceutical economics and policy, health care financing, health care negotiations, and principles of health technology assessment. Panos’ areas of expertise in pharmaceutical and medical technology policy, pricing, health technology assessment, and digital health, have attracted significant interest by many national governments, as well as international and supranational organisations, in terms of implementing pharmaceutical policy reform and adopting new methods of assessing medicines and new technologies altogether. His work has had impact across geographies in addressing, among others, issues related to (a) health care financing reform and population health management; (b) the broad parameters of pharmaceutical policy and value assessment, (c) formulating policy framework for generic medicines, for advanced diagnostics, and for digital health technologies, (d) studying the clinical, economic, social and other criteria based on which countries make coverage decisions for new technologies, including medicines, medical devices and digital health tools; and (e) contributing to important policy developments, such as the drafting of the EU Regulation on HTA cooperation.
Panos was one of the co-authors of the impact assessment report, published in August 2017 by the European Commission, which provided the intellectual and empirical backdrop for the drafting of the EU HTA Regulation (HTAR), which was adopted at EU level in 2022 and implemented on January 10th 2025. Much of this work has been undertaken under his direction by the Medical Technology Research Group (MTRG) at 911勛圖Health.
Panos has acted as advisor to a number of international governmental and non-governmental organizations, including the European Commission, the European Parliament, the World Bank, the World Health Organization, the Organization for Economic Co-operation and Development (OECD), the American Association for Retired Persons, and Ministries of Health/Health Insurance Organisations in over 50 high-, upper middle- and lower-to-middle-income countries. Areas of Panos’ formal engagement with governmental and non-governmental bodies have included country missions, support for reform initiatives, and ad hoc advice on strategy to undertake, legislate and implement health reform agendas in the Americas, Europe, the Middle East and North Africa, and Asia. Topics have included:
(a) pharmaceutical policy, with emphasis on pricing, financing, reimbursement of medicines;
(b) distribution of medicines and supply chain reform;
(c) behavioural change and incentives and their impact on coverage and reimbursement mechanisms;
(d) design of risk-sharing agreements and legislation drafting on risk mitigation strategies;
(e) health technology assessment (methods, governance, implementation guidance);
(f) hospital financing reform;
(g) universal health coverage & benefit package definition; and
(h) competition in health care markets and anti-trust legislation.